Letrozole and Misoprostol for Early Pregnancy Loss Management

Launched by UNIVERSITY OF PENNSYLVANIA · Jun 5, 2024

Keywords

ClinConnect Summary

This clinical trial is exploring a new treatment approach for managing early pregnancy loss, often referred to as a miscarriage. The study is looking at whether taking a medication called letrozole for three days, followed by another medication called misoprostol, can help women who have been diagnosed with an early pregnancy loss. The researchers want to see how effective this combination is, any side effects that may occur, and how acceptable the treatment is to patients.

To participate in this study, women must be at least 18 years old, speak English, and have a confirmed diagnosis of early pregnancy loss, which is identified through an ultrasound. Participants will need to agree to follow the study's procedures and should have access to a mobile phone for communication. If you are interested in learning more or think you might qualify, please reach out for more information. Your involvement could help improve care for future patients facing similar challenges.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Able to participate in the informed consent process and provide a signed and dated consent form
• • Stated willingness to comply with all study procedures and availability for the duration of the study
• • Access to working mobile phone
• • English-speaking
• • Age 18 years or older
• • Confirmed diagnosis of intrauterine embryonic/fetal demise or anembryonic gestation (ultrasound examination demonstrates a fetal pole without cardiac activity measuring between 5.3 and 40 mm or an abnormal growth pattern diagnostic of early pregnancy failure)
• Exclusion Criteria:
• • Incomplete or inevitable abortion
• • Contraindication of allergy to letrozole or misoprostol
• • Unable to return for clinic-based follow-up
• • Twin or multiple pregnancy